Skip to main content
Premium Trial:

Request an Annual Quote

Sylvie Grégoire, James Mullen

Sylvie Grégoire has been elected to the board of PerkinElmer. She has more than 30 years of industry experience and most recently served for seven years as the president of human genetic therapies at Shire. Prior to that, she was executive chairwoman of IDM Pharma, currently a subsidiary of Takeda Pharmaceuticals. She also has been president and CEO of GlycoFi and held leadership, regulatory, and clinical research positions at Biogen and Merck. Grégoire is currently a board member of Galenica.

The firm also said that James Mullen has decided not to stand for re-election as a director of the company at the annual meeting of shareholders to be held on April 28, 2015.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.